Sampo plc: Managers’ Transactions (Clausen)
SAMPO PLC MANAGERS’ TRANSACTIONS 10 November 2023 at 3:00 pm
Sampo plc: Managers’ Transactions (Clausen)
Sampo plc (business code 0142213-3) has received the following notification under Article 19 of the Market Abuse Regulation. Shares have been acquired in accordance with the decision of Sampo's Annual General Meeting on 17 May 2023.
____________________________________________
Person subject to the notification requirement
Name: Christian Clausen
Position: Member of the Board/Deputy member
Issuer: Sampo plc
LEI: 743700UF3RL386WIDA22
Notification type: INITIAL NOTIFICATION
Reference number: 43192/8/6
____________________________________________
Transaction date: 2023-11-09
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI4000552500
Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE
Transaction details
(1): Volume: 660 Unit price: 38.4713 EUR
Aggregated transactions (1):
Volume: 660 Volume weighted average price: 38.4713 EUR
____________________________________________
SAMPO PLC
Sami Taipalus
Head of Investor Relations
tel. +358 10 516 0030
Distribution:
Nasdaq Helsinki
Nasdaq Stockholm
London Stock Exchange
FIN-FSA
The principal media
www.sampo.com
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology7.12.2023 03:30:00 CET | Press release
R&D Day Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology Details strong pipeline including Sanofi’s record 12 blockbuster opportunities under clinical evaluation: 9 innovative medicines and vaccines with €2 to 5 billion peak sales potential, and 3 ‘pipeline-in-a-product’ assets with a potential of over €5 billion peak sales Strategic transformation through R&D features potential multi-indication assets such as amlitelimab, frexalimab and the oral TNFR1si intended to address unmet patient needs in markets with low penetration of advanced therapiesEnhanced R&D focus aims to deliver a 50% increase in Phase 3 trials in 2024 and 2025 as well as 25 mid- to late-stage read-outs over the next 2 yearsAmbition to become an immunology powerhouse driven by recent and future launched pharma assets, generating over €10 billion in annual sales by 2030, in addition to the strong growth of
Bombardier Completes Redemption for All of its 7.50% Senior Notes due 20256.12.2023 23:01:00 CET | Press release
MONTRÉAL, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Bombardier Inc. (“Bombardier”) today announced that it has redeemed all of its outstanding US$380 million aggregate principal amount of its 7.50% Senior Notes due 2025 (the “Redemption Notes”), as set forth in the notice of redemption issued November 6, 2023. Payment of the redemption price and surrender of the Redemption Notes for redemption are being made through the facilities of the Depository Trust Company in accordance with their applicable procedures. This press release does not constitute an offer to sell or buy or the solicitation of an offer to buy or sell any security and shall not constitute an offer, solicitation, sale or purchase of any securities in any jurisdiction in which such offering, solicitation, sale or purchase would be unlawful. The securities mentioned herein have not been and will not be registered under the United States Securities Act of 1933, as amended, any state securities laws or the laws of any other jurisdic
CNH Industrial: Periodic Report on $1 Billion Buyback Program6.12.2023 22:30:00 CET | Press release
CNH Industrial: Periodic Report on $1 Billion Buyback Program Basildon, December 6, 2023 CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) announces that under the €400 million component (the “First Component”) of its $1 billion share buyback program the Company completed transactions in the period November 27, 2023 through November 28, 2023, reported in aggregate, as set forth in the table below. After the purchases announced today and considering those previously executed under the First Component, the total invested amount in the First Component is approximately €187,597,638.20 ($203,388,077.50) or a total amount of 20,060,075 common shares purchased. DateNumber of common shares purchasedAverage price per share excluding feesConsideration excluding fees Consideration (*) excluding fees(€)(€)($) November 27,2023 1,500,000 9.3947 14,092,050.00 15,432,203.96 November 28,2023 1,000,000 9.5264 9,526,400.00 10,430,455.36 2,500,000 - 23,618,450.0025,862,659.32 (*) All translations determined fro
Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry6.12.2023 22:00:09 CET | Press release
Believed to be first ever psilocybin clinical trial for treatment of bipolar II depression LONDON, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a paper in JAMA Psychiatry that demonstrates the potential for investigational COMP360 psilocybin treatment in treatment-resistant bipolar type II disorder (bipolar II). Results from the investigator-initiated open-label study were first presented at the Annual Meeting of the American College of Neuropsychopharmacology in 2022. The study, which was conducted by Dr Scott Aaronson at Sheppard Pratt, Baltimore, and funded by Compass, investigated the safety and efficacy of a single 25mg dose of COMP360 psilocybin treatment in participants with treatment-resistant bipolar II. The primary endpoint was change in Montgomery-Åsberg Depression Rating Scale (MADRS) total s
SustainableIT.org Announces Commitment to Elevate Technology Leadership in Global Sustainability Efforts at COP286.12.2023 20:25:50 CET | Press release
REDWOOD CITY, California, Dec. 06, 2023 (GLOBE NEWSWIRE) -- SustainableIT.org, a leading nonprofit organization championed by technology executives, today affirmed its commitment to advancing global sustainability through information technology innovation and leadership. This announcement comes as a strategic response to the ongoing COP28 United Nations Climate Change Conference, emphasizing the need for a stronger technology presence in sustainability dialogues and decision-making processes. The COP28 event underscores the urgent need for a global conversation on sustainability strategy. However, it also highlights a significant gap: the limited involvement of digital, data, and information technology leaders in these critical discussions. Floor Bleeker, Group Chief Technology Officer of Accor and member of SustainableIT.org’s European Advisory Board, is one of the technology executives participating in this year's conference. Bleeker will be speaking on a panel with ServiceNow on Dec